{"data":{"responsecode":"000","responsemsg":"","quote":{"hi":"35.540","rs_stock_flag":false,"fiscal_year_end":"2024年12月31日","hist_closedate":"2025年9月25日","replication_method":null,"amt_os":"6,055,150,070","primaryexch":"香港交易所","ric":"3692.HK","product_subtype":null,"db_updatetime":"2025年9月28日08:06","mkt_cap_u":"B","am_u":"M","ew_sub_right":"","secondary_listing":false,"ew_amt_os_cur":null,"ccy":"HKD","management_fee":"","ew_underlying_code":null,"trdstatus":"N","nav":"","original_offer_price":"","issue":"","asset_class":null,"eps":0.7372,"inline_upper_strike_price":"","sedol":"BJYKB72","am":"226.15","iv":"","ew_strike":"","as":"34.840","geographic_focus":null,"incorpin":"開曼群島","etp_baseCur":null,"ew_amt_os":"","bd":"34.800","registrar":"卓佳證券登記有限公司","depositary":null,"exotic_type":null,"callput_indicator":null,"primary_market":null,"underlying_index":null,"lot":"2,000","update_time":"2025-09-28 00:06:03.0","lo52":"15.960","shares_issued_date":"2025年8月31日","premium":"","strike_price_ccy":null,"yield":"","vo_u":"M","base_currency":null,"coupon":"","expiry_date":"","chairman":"鍾慧娟","underlying_ric":"3692.HK","hi52":"39.760","issuer_name":"翰森製藥集團有限公司","h_share_flag":false,"ew_sub_per_from":"","div_yield":"1.05","interest_payment_date":"-","updatetime":"2025年9月26日16:08","aum_date":"","lo":"34.600","mkt_cap":"210.96","f_aum_hkd":null,"ew_sub_per_to":"","ls":"34.840","nav_date":"","csic_classification":null,"floating_flag":false,"issued_shares_note":null,"nom_ccy":null,"eff_gear":"","board_lot_nominal":null,"hsic_ind_classification":"醫療保健業 - 藥品及生物科技","ew_desc":null,"inception_date":"","nc":"-0.720","aum":"","issued_shares_class_B":null,"vo":"6.48","secondary_listing_flag":false,"listing_date":"2019年6月14日","issued_shares_class_A":null,"as_at_label":"截至","ew_amt_os_dat":"","nm":"翰森製藥集團有限公司","nm_s":"翰森製藥","sym":"3692","inline_lower_strike_price":"","listing_category":"主要上市","ew_strike_cur":null,"exotic_warrant_indicator":null,"investment_focus":null,"call_price":"","tck":"0.020","strike_price":"","summary":"翰森製藥集團有限公司是一家主要從事一系列藥品的研發、生產及銷售的投資控股公司。該公司的創新藥產品包括阿美樂、豪森昕福、邁靈達、孚來美、恒沐、昕越、聖羅萊等產品。該公司的創新藥產品主要應用於抗腫瘤、抗感染、中樞神經系統（CNS）疾病、代謝及其他治療領域。該公司主要在國內市場開展業務。","op":"35.020","aum_u":"","nav_ccy":null,"class_B_description":null,"os":"","wnt_gear":"","transfer_of_listing_date":"","hsic_sub_sector_classification":"藥品","amt_ccy":null,"class_A_description":null,"domicile_country":null,"entitlement_ratio":"","product_type":"EQTY","office_address":"香港銅鑼灣<br/>希慎道33號<br/>利園一期<br/>19樓1928室","pc":"-2.02","days_to_expiry":null,"underlying_code":null,"pe":"44.60","eps_ccy":"RMB","hdr":false,"launch_date":"","hc":"35.560","isin":"KYG549581067","moneyness":""}},"qid":"1759074073637"}
